Affordable Access

deepdyve-link
Publisher Website

Chromogranin A is a T cell antigen in human type 1 diabetes.

Authors
  • Gottlieb, Peter A1
  • Delong, Thomas2
  • Baker, Rocky L3
  • Fitzgerald-Miller, Lisa4
  • Wagner, Rebecca5
  • Cook, Gabrielle6
  • Rewers, Marian R7
  • Michels, Aaron8
  • Haskins, Kathryn9
  • 1 Barbara Davis Center for Diabetes, 1775 Aurora Ct, Aurora, CO 80045, USA. Electronic address: [email protected]
  • 2 Integrated Department of Immunology, University of Colorado at Denver School of Medicine and National Jewish Health, 1400 Jackson Street, Denver, CO 80205, USA. Electronic address: [email protected]
  • 3 Integrated Department of Immunology, University of Colorado at Denver School of Medicine and National Jewish Health, 1400 Jackson Street, Denver, CO 80205, USA. Electronic address: [email protected]
  • 4 Barbara Davis Center for Diabetes, 1775 Aurora Ct, Aurora, CO 80045, USA. Electronic address: [email protected]
  • 5 Barbara Davis Center for Diabetes, 1775 Aurora Ct, Aurora, CO 80045, USA. Electronic address: [email protected]
  • 6 Barbara Davis Center for Diabetes, 1775 Aurora Ct, Aurora, CO 80045, USA. Electronic address: [email protected]
  • 7 Barbara Davis Center for Diabetes, 1775 Aurora Ct, Aurora, CO 80045, USA. Electronic address: [email protected]
  • 8 Barbara Davis Center for Diabetes, 1775 Aurora Ct, Aurora, CO 80045, USA. Electronic address: [email protected]
  • 9 Integrated Department of Immunology, University of Colorado at Denver School of Medicine and National Jewish Health, 1400 Jackson Street, Denver, CO 80205, USA. Electronic address: [email protected]
Type
Published Article
Journal
Journal of Autoimmunity
Publisher
Elsevier
Publication Date
May 01, 2014
Volume
50
Pages
38–41
Identifiers
DOI: 10.1016/j.jaut.2013.10.003
PMID: 24239002
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Chromogranin A (ChgA) is a beta cell secretory granule protein and a peptide of ChgA, WE14, was recently identified as a ligand for diabetogenic CD4 T cell clones derived from the NOD mouse. In this study we compared responses of human CD4 T cells from recent onset type 1 diabetic (T1D) and control subjects to WE14 and to an enzymatically modified version of this peptide. T cell responders to antigens were detected in PBMCs from study subjects by an indirect CD4 ELISPOT assay for IFN-γ. T1D patients (n = 27) were recent onset patients within one year of diagnosis, typed for HLA-DQ8. Controls (n = 31) were either 1st degree relatives with no antibodies or from the HLA-matched general population cohort of DAISY/TEDDY. A second cohort of patients (n = 11) and control subjects (n = 11) was tested at lower peptide concentrations. We found that WE14 is recognized by T cells from diabetic subjects vs. controls in a dose dependent manner. Treatment of WE14 with transglutaminase increased reactivity to the peptide in some patients. This work suggests that ChgA is an important target antigen in human T1D subjects and that post-translational modification may play a role in its reactivity and relationship to disease. Copyright © 2013 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times